کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2199765 | 1099617 | 2013 | 5 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacy Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: Biomarker of long-term drug efficacy](/preview/png/2199765.png)
Using an acute promyelocytic leukemia (APL) preclinical model, we show that oncogene–specific PCR (Polymerase Chain Reaction)-based assays allow to evaluate the efficacy of immunotherapy combining all-trans retinoic acid (ATRA) and a DNA-based vaccine targeting the promyelocytic leukemia-retinoic acid receptor alpha (PML-RARα) oncogene. Kaplan–Meier survival analysis according to the peripheral blood PML-RARα normalized copy number (NCN) clearly shows that ATRA + DNA-treated mice with an NCN lower than 10 (43%) formed the group with a highly significant (p < 0.0001) survival advantage. Furthermore, a PCR assay was used to assess various tissues and organs for the presence of PML-RARα-positive cells in long-term survivors (n = 15). As expected, the majority of mice (n = 10) had no measurable tissue level of PML-RARα. However, five mice showed a weak positive signal in both the brain and spleen (n = 2), in the brain only (n = 2) and in the spleen only (n = 1). Thus tracking the oncogene-positive cells in long-term survivors reveals for the first time that extramedullary PML-RARα-positive cell reservoirs such as the brain may persist and be involved in relapses.
Journal: Molecular and Cellular Probes - Volume 27, Issue 1, February 2013, Pages 1–5